Diurnal prepares to launch Infacort in 2018

25 January 2017

Anticipating an early 2018 launch for Infacort (hydrocortisone), Diurnal Group (AIM: DNL) has signed an agreement with two subsidiaries of UDG Healthcare (LSE: UDG) to build up sales and medical infrastructure in the European Union.

Infacort is a novel hydrocortisone preparation designed for use in children suffering from adrenal insufficiency, a rare disease which affects 4,000 young children in Europe. There is currently no treatment option in Europe specifically designed to treat these patients.

The UK-based specialty pharmaceutical company submitted a Pediatric Use Marketing Authorization to the European Medicines Agency in late 2016.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK